Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2',6'-difluorophenyl)-1H,3H-thiazolo[3,4-a] benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 4, 1997, Pages 363-370

  Chimirri, A ^a   Grasso, S ^a   Molica, C ^a   Monforte, A M ^a   Monforte, P ^a   Zappala M ^a   Bruno, G ^a   Nicolo F ^a   Witvrouw, M ^b   Jonckeere, H ^b   Balzarini, J ^b   De Clercq, E ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Absolute configuration; antiviral; HIV; NNRTI; TBZ; Thiazolobenzimidazole

Indexed keywords

9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG CONFORMATION; DRUG RESISTANCE; DRUG SOLUTION; DRUG STRUCTURE; ENANTIOMER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROGEN BOND; ISOMER; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID STATE; STEREOCHEMISTRY; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

EID: 0030814399     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029700800409     Document Type: Article

References (38)

1. Aboul-Enein HY & Islam MR (1991) Direct HPLC separation of thalidomide enantiomers using cellulose tris-4-methylphenyl benzoate chiral stationary phase. Journal of Liquid Chromatograph 14: 667-673.
2. Allen FH, Davies JE, Galloy JJ, Johnson O, Kennard O, Macrae CF, Mitchell EM, Mitchell GF, Smith JM & Watson DG (1991) The development of version 3 and 4 of the Cambridge structural database system. Journal of Chemical Information and Computer Sciences 31: 187-204.
3. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J & De Clercq E (1993a) Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196: 576-585.
4. Balzarini J, Karlsson A, Pérez-Pérez M-J, Camarasa M-J, Tarpley WG & De Clercq E (1993b) Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Journal of Virology 67: 5353-5359.
5. Balzarini J, Karlsson A, Pérez-Pérez M-J, Vrang L, Walbers J, Zhang H, Öberg B, Vandamme A-M, Camarasa M-J & De Clercq E (1993c) HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitution in the reverse transcriptase. Virology 192: 246-253.
6. Balzarini J, Karlsson A & De Clercq E (1993d) Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine derivatives. Molecular Pharmacology 44: 694-701.
7. Balzarini J, Aquaro S, Perno C-F, Witvrouw M, Holy A & De Clercq E (1996) Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochemical and Biophysical Research Communications 219: 337-341.
8. Bernardinelli G & Flack HD (1985) Least-squares absolute-structure refinement. Practical experience and ancillary calculations. Acta Crystallographica Section A 41: 500-511.
9. Bruno G, Monforte AM, Nicolò F, Scopelliti R & Zappalà M (1996) 1-(3,5-Ditrifluoromethylphenyl)-1H,3H-thiazolo[3,4-a]benzimidazole. Acta Cryststallographica Section C 52: 2533-2535.
10. Buckheit RW, Hollinshead MG, Germany-Decker J, White EL, McMahon JB, Allen LB, Ross LJ, Decker WD, Westbrook L, Shannon WM, Weislow O, Bader JP & Boyd MR (1993) Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor. Antiviral Research 21: 247-265.
11. Chimirri A, Grasso S, Monforte AM, Monforte P & Zappalà M (1991a) Anti-HIV agents I: synthesis and in vitro anti-HIV evaluation of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 46: 817-823.
12. Chimirri A, Grasso S, Monforte AM, Monforte P & Zappalà M (1991b) Anti-HIV agents II: synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 46: 925-933.
13. Chimirri A, Grasso S, Monforte AM, Monforte P & Zappalà M (1994) Anti-HIV agents III: synthesis and in vitro anti-HIV activity of novel 1H,3H-thiazolo[3,4-a]imidazo[4,5-b]pyridines. Il Farmaco 49: 345-348.
14. Chimirri A, Grasso S, Molica C, Monforte AM, Monforte P & Zappalà M (1996) Anti-HIV agents IV: synthesis and in vitro anti-HIV activity of novel 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazoles. Il Farmaco 51: 279-282.
15. Connolly KJ & Hammer SM (1992) Antiretroviral therapy: reverse transcriptase inhibition. Antimicrobial Agents and Chemotherapy 36: 245-254.
16. De Clercq E (1993) HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Medicinal Research Reviews 13: 229-258.
17. De Clercq E (1994a) Non-nucleoside reverse transcriptase inhibitors (NNRTIs). Expert Opinions in Investigational Drugs 3: 253-271.
18. De Clercq E (1994b) HIV resistance to reverse transcriptase inhibitors. Biochemical Pharmacology 47: 155-169.
19. De Clercq E (1995a) Antiviral therapy of human immunodeficiency virus infections. Clinical Microbiology Reviews 8: 200-239.
20. De Clercq E (1995b) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. Journal of Medicinal Chemistry 38: 2491-2517.
21. De Clercq E & Balzarini J (1995) Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combination: a paradigm for the cure of AIDS. Il Farmaco 50: 735-747.
22. Diamond R (1969) Profile analysis in single crystal diffractometry. Acta Crystallographica Section A 25: 43-55.
23. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PAJ, Hughes SH & Arnold E (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse non-nucleoside inhibitors. Nature Structural Biology 2: 407-415.
24. El Dareer SM, Tillery KF, Rose LM, Posey CF, Struck RF, Stiller SW & Hill DL (1993) Metabolism and disposition of a thiazolobenzimidazole active against human immunodeficiency virus-1. Drug Metabolism and Disposition 21: 231-235.
25. Ficarra R, Calabrò ML, Tommasini S, Grasso S, Carulli M, Monforte AM, Costantino D & Ficarra P (1995) Enantiomeric resolution of anti-HIV agents on a cellulose derivative chiral stationary phase. Note II. Chromatographia 40: 39-41.
26. Hizi A, Tal R, Shaharabany M, Currens MJ, Boyd MR, Hughes SH & McMahon JB (1993) Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrobial Agents and Chemotherapy 37: 1037-1042.
27. 138→Lys on the p51 subunit. Journal of Biological Chemistry 269: 25255-25258.
28. Kopfmann G & Huber R (1968) A method of absorption correction by X-ray intensity measurements. Acta Crystallographica Section A 24: 348-351.
29. Nardelli M (1983) PARST: a system of FORTRAN routines for calculating molecular structure parameters from results of crystal structure analyses. Computational Chemistry 7: 95-98.
30. Scafer W, Friebe WG, Leinert H, Mertens A, Poll T, von der Saal W, Zilch H, Nuber B & Ziegler ML (1993) Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations. Journal of Medicinal Chemistry 36: 726-732.
31. Schinazi RF (1993) Competitive inhibitors of human immunodeficiency virus reverse transcriptase. Perspectives on Drug Discovery and Design 1: 151-180.
32. Schinazi RF, Mead JR & Feorino PM (1992) Insights into HIV chemotherapy. AIDS Research and Human Retroviruses 8: 963-990.
33. Schultz RJ, Bader JP, Chimirri A, Covey JM, Hill DL, Haugwitz RD, Guziec FS & Narayanan VL (1992) Thiazolobenzimidazoles - a new class of anti-HIV agents. Proceedings of the American Association for Cancer Research 33: 517.
34. Sheldrick GM (1990a) SHELXTL-Plus, version 4.2. Madison: Siemens Analytical Instruments.
35. Sheldrick GM (1990b) Phase annealing in SHELX-90: direct methods for larger structures. Acta Crystallographica Section A 46: 467-473.
36. Sheldrick GM, Dauter Z, Wilson KS, Hope H & Sieker LC (1993) The application of direct methods and Patterson interpretation to high-resolution native protein data. Acta Crystallographica Section D 49: 18-23.
37. Tinwalla AY, Hoesterey BL, Xiang T & Anderson BD (1993) Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation with 2-hydroxypropyl-β cyclodextrin. Pharmaceutical Research 10: 1136-1143.
38. Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH & Boyd MR (1989) New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. Journal of the National Cancer Institute 81: 577-586.